Skip to main content

Advertisement

Table 3 Multivariable analysis of letrozole versus tamoxifen treatment effect by tumor AR expression

From: Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1–98

   All monotherapy AR+ AR− P-Hetc
Individuals Events HR (95% CI) HR (95% CI) HR (95% CI)
Breast cancer-free interval
 Model 1a 1753 236 0.67 (0.52–0.87) 0.73 (0.55–0.98) 0.49 (0.27–0.87) 0.22
p = 0.003 p = 0.03 p = 0.02  
 Model 2b 1697 227 0.57 (0.44–0.75) 0.63 (0.47–0.85) 0.39 (0.21–0.72) 0.16
p < 0.001 p = 0.003 p = 0.002  
Disease-free survival
 Model 1 1753 401 0.75 (0.62–0.92) 0.80 (0.64–0.99) 0.61 (0.39–0.94) 0.27
p = 0.005 p = 0.04 p = 0.03  
 Model 2 1697 388 0.69 (0.56–0.84) 0.73 (0.59–0.92) 0.52 (0.33–0.83) 0.19
p < 0.001 p = 0.008 p = 0.005  
  1. AR expression is defined as ≥ 1% positive, < 1% negative. This analysis is restricted to 1753 patients who received letrozole or tamoxifen monotherapy
  2. aModel 1: Stratified by receipt of chemotherapy and adjusted for age at randomization, AR expression (all monotherapy analysis only)
  3. bModel 2: Model 1 + adjusted for tumor size, lymph node involvement, local therapy, ER, PR, HER2, and Ki67 expression
  4. cP value is from test of heterogeneity of treatment effect in AR+ and AR− cancers